| Title |
Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder
|
|---|---|
| Published in |
Psychopharmacology, December 2011
|
| DOI | 10.1007/s00213-011-2604-x |
| Pubmed ID | |
| Authors |
Robert Riesenberg, Joshua Rosenthal, Leslie Moldauer, Christine Peterson |
| Abstract |
RX-10100 (Serdaxin®), a nonantibiotic small molecule beta-lactam compound, has shown potent antidepressant and anxiolytic activities in preclinical models. RX-10100 does not bind to the serotonin transporter or other receptors associated with monoamine activity. In microdialysis studies with rats, RX-10100 increased the release of dopamine and serotonin metabolites. A clinical proof-of-concept study was conducted to determine the clinical effectiveness of RX-10100 in treating depression. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 50% |
| United States | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 45 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 22% |
| Researcher | 8 | 18% |
| Student > Ph. D. Student | 7 | 16% |
| Lecturer | 1 | 2% |
| Student > Doctoral Student | 1 | 2% |
| Other | 5 | 11% |
| Unknown | 13 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 8 | 18% |
| Medicine and Dentistry | 8 | 18% |
| Agricultural and Biological Sciences | 3 | 7% |
| Neuroscience | 2 | 4% |
| Social Sciences | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 16 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2011.
All research outputs
#15,288,322
of 25,708,267 outputs
Outputs from Psychopharmacology
#3,930
of 5,353 outputs
Outputs of similar age
#157,895
of 251,091 outputs
Outputs of similar age from Psychopharmacology
#25
of 37 outputs
Altmetric has tracked 25,708,267 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,353 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,091 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.